Paper427798
Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE and 3 others. Cancer Res, 1979. Cited by 196 papers, by iCite.
Cite this record
ConductScience Library. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Papers, record 427798. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/427798
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anthracenes | Major topic |
| Antineoplastic Agents | Major topic |
| Neoplasms, Experimental | Major topic |
| Animals | |
| Colonic Neoplasms | |
| Injections | |
| Leukemia, Experimental | |
| Lung Neoplasms | |
| Male | |
| Melanoma | |
| Mice | |
| Mice, Inbred Strains |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 196 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34671088 | Genetic landscape of T cells identifies synthetic lethality for T-ALL. | Commun Biol | 2021 | https://conductscience.org/library/papers/34671088 | PubMed |
| 25295084 | Salvage therapy with mitoxantrone, etoposide, bleomycin and dexamethasone for refractory or relapsed aggressive non-Hodgkin's lymphoma patients with a poor performance status or comorbidity. | Oncol Lett | 2014 | https://conductscience.org/library/papers/25295084 | PubMed |
| 17483512 | Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent. | Nucleic Acids Res | 2007 | https://conductscience.org/library/papers/17483512 | PubMed |
| 10091119 | Major versus minor groove DNA binding of a bisarginylporphyrin hybrid molecule: a molecular mechanics investigation. | J Comput Aided Mol Des | 1999 | https://conductscience.org/library/papers/10091119 | PubMed |
| 7460190 | Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug. | Cancer Chemother Pharmacol | 1980 | https://conductscience.org/library/papers/7460190 | PubMed |
| 7105379 | Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7105379 | PubMed |
| 7094196 | Pharmacology of mitoxantrone in cancer patients. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/7094196 | PubMed |
| 6690066 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6690066 | PubMed |
| 6687221 | Correlation of the structure of amino-substituted anthraquinones to cytotoxicity in cultured Chinese hamster cells. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6687221 | PubMed |
| 6678863 | Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678863 | PubMed |
| 6678857 | Mitoxantrone hydrochloride (NSC-310739) in lymphoma. A Southwest Oncology Group study. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678857 | PubMed |
| 6544900 | Plasma kinetics of mitoxantrone in leukemic patients. | Med Oncol Tumor Pharmacother | 1984 | https://conductscience.org/library/papers/6544900 | PubMed |
| 6416699 | Cooperative studies of systemic chemotherapy. A review of the work of the EORTC Urological Group and of the Yorkshire Urological Cancer Research Group (YUCRG). | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6416699 | PubMed |
| 4019123 | Mitoxantrone in malignant lymphoma. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/4019123 | PubMed |
| 4019122 | Mitoxantrone in refractory acute leukemia in children: a phase I study. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/4019122 | PubMed |
| 3894277 | A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3894277 | PubMed |
| 3860490 | Mitoxantrone in the treatment of relapsed and refractory acute leukemia. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/3860490 | PubMed |
| 3733373 | Investigation of the interaction of cardiotoxic anticancer agents using the fetal mouse heart organ culture system. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3733373 | PubMed |
| 3700041 | A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3700041 | PubMed |
| 3700039 | Novantrone for childhood malignant solid tumors. A pediatric oncology group phase II study. | Invest New Drugs | 1986 | https://conductscience.org/library/papers/3700039 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/427798
GET https://conductscience.org/api/papers/v1/427798/cited_by?page=2